Aprea Therapeutics is a Boston, Massachusetts and Stockholm, Sweden based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. Aprea Therapeutics is focused on the development of novel therapeutic agents that induce p53-mediated cancer cell death by restoring normal function to mutated p53. Aprea has commenced a Phase 3 clinical study in p53 mutated MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutated high-risk MDS and oligoblastic AML.


-- Advertisement --